Navigation Links
Circulation Publishes Pivotal Two-Year Results On XIENCE V(TM) Drug Eluting Stent
Date:1/26/2009

stent and treat the diseased portion of the artery.

The XIENCE V stent is available on both over-the-wire (OTW) and rapid exchange (RX) delivery systems. Rapid exchange is the most widely used type of delivery system because it provides physicians additional flexibility to work as single operators during stent procedures.

XIENCE V was approved by the U.S. Food and Drug Administration and launched in July 2008, and was launched in Europe and other international markets in October 2006. XIENCE V is an investigational device in Japan and is currently under review by the Ministry of Health, Labour and Welfare and the Pharmaceuticals and Medical Devices Agency.

Abbott also supplies a private-labeled XIENCE V to Boston Scientific called the PROMUS(TM) Everolimus-Eluting Coronary Stent System. PROMUS is manufactured by Abbott and supplied to Boston Scientific as part of a distribution agreement between the two companies.

Everolimus, developed by Novartis Pharma AG, is a proliferation signal inhibitor, or mTOR inhibitor, licensed to Abbott by Novartis for use on its drug eluting stents. Everolimus has been shown to inhibit in-stent neointimal growth in the coronary vessels following stent implantation, due to its anti- proliferative properties.

Additional information about XIENCE V, including important safety and effectiveness information, is available online at http://www.xiencev.com.

About Abbott Vascular

Abbott Vascular, a division of Abbott, is one of the world's leading vascular care businesses. Abbott Vascular is uniquely focused on advancing the treatment of vascular disease and improving patient care by combining the latest medical device innovations with world-class pharmaceuticals, investing in research and development, and advancing medicine through training and education. Headquartered in
'/>"/>

SOURCE Abbott
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Circulation Publishes Data Showing KYNAPID(TM) (Vernakalant Hydrochloride) Injection Rapidly Converted Short-Duration Atrial Fibrillation to Sinus Rhythm
2. Regado Biosciences Announces Publication in Circulation of Clinical Trial Results of REG1 Anticoagulation System
3. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
4. The Lancet Publishes Major Phase 3 Study on Novel Oral Direct Thrombin Inhibitor
5. The New England Journal of Medicine Publishes First Clinical Results for MedImmunes Chitinase-like Protein YKL-40 in Patients With Asthma
6. Biological Psychiatry Publishes Study Showing VYVANSE Demonstrated Significant Efficacy for Treatment of ADHD for up to 12 Hours After Administration
7. Franklin & Seidelmann Publishes Complex Podiatry MRI Study
8. ImQuest Publishes Results of Important Structure Activity Relationship Program on Dual Acting Pyrimidinediones
9. Video: The Journal, Human Genetics, Publishes Results Supporting Interleukin Genetics Heart Health Test
10. Jennerex Publishes Promising Results from Cancer Clinical Trial of JX-594 in Lancet Oncology
11. New England Journal of Medicine Publishes Results From a RELISTOR Phase 3 Clinical Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... , Dec. 17, 2014  RXi Pharmaceuticals ... company focused on discovering, developing and commercializing innovative ... technologies, today announced completion of enrollment in its first ... the 3-month observations confirmed the 1-month findings that ... Logo - http://photos.prnewswire.com/prnh/20130917/NE80755LOGO ...
(Date:12/15/2014)... , Dec. 12, 2014 Research and Markets ... addition of the "MEMS Gyroscopes Analog Devices ... report to their offering. ... for tactical grade applications made a lot of ... of reliability. They are now accepted in high-reliability ...
(Date:12/15/2014)... 15, 2014 BerGenBio AS, a ... drug resistant cancers, today announces that it has raised ... from new and existing investors. BerGenBio will ... development of its pipeline of innovative cancer therapeutics, in ... drug candidate, BGB324, a first-in-class selective Axl kinase inhibitor, ...
Breaking Medicine Technology:RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 2RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 3RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 4RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 5MEMS Gyroscopes Analog Devices ADIS16136 Precision Angular Rate Sensor Reverse Costing Analysis 2BerGenBio Completes NOK90 Million Fundraising 2
(Date:12/19/2014)... Norton HealthDay Reporter THURSDAY, ... who were exposed to high levels of air pollution late ... a U.S. study suggests. Researchers found that of nearly ... those exposed to the most air pollution during pregnancy were ... autism. And exposure during the third trimester, specifically, showed the ...
(Date:12/19/2014)... Dec. 18, 2014 (HealthDay News) -- Prostaglandin analogue eye ... significantly reduce the risk of vision loss in patients ... British researchers led by David Garway-Heath, of the Moorfields ... tracked outcomes for more than 500 people newly diagnosed ... the disease and one of the leading causes of ...
(Date:12/17/2014)... Myo Nwe is the co-author of a new weight loss ... of the Ace Medical Weight Loss Center in Rock Hill, ... at the industry of weight loss, and how several fad ... in television shows, however, she says the topic of obesity ... for basic laughs, which she believes impacts whether Americans view ...
(Date:12/17/2014)... HeartMath® Inc., recognized as one of ... variability (HRV), heart coherence and the physiology of ... and algorithms to chipset manufacturers and consumer electronics ... to offer its HRV solutions, tap into its ... its normative HRV databases and algorithms for developing ...
(Date:12/17/2014)... (PRWEB) December 17, 2014 No matter ... been able to eradicate the head louse parasite—a common ... for parents. Each year between six and twelve million ... the Miami-based lice removal treatment company comes to the ... and environmentally friendly. With its track record of customer ...
Breaking Medicine News(10 mins):Health News:Smog Exposure During Pregnancy Linked to Autism Risk 2Health News:Smog Exposure During Pregnancy Linked to Autism Risk 3Health News:Study Supports Benefit of Widely Used Glaucoma Drug 2Health News:Obesity Should Not Be a Hollywood Punchline, Weight Loss Doc Says 2Health News:HeartMath® Inc.’s HRV Platform Solutions Available for Licensing 2Health News:HeartMath® Inc.’s HRV Platform Solutions Available for Licensing 3Health News:Lice Troopers Announces New Lice Treatment Clinic in Coral Gables to Service Key Biscayne, Coconut Grove, Kendall, Brickell & South Miami 2
... Jerry Posakony, scientist at the Department of Energy,s Pacific ... Association of Engineering Societies for his pioneering contributions to ... evaluation technologies. AAES has awarded the John Fritz ... engineer and 15th president of the American Society of ...
... finds 3 percent of those who get something lodged in ... Although the number of young children who choke after swallowing ... when that happens is real, the latest research indicates. , ... study author Dr. Rahul K. Shah, a pediatric otolaryngologist with ...
... researchers in the University of Alabama at Birmingham (UAB) ... identify potential dangers on playgrounds and in gymnasiums and ... The tools consist of two checklists that ... facilities and equipment on playgrounds and in gymnasiums. The ...
... The ... 146 medical schools and schools of osteopathic medicine nationwide, jumping from 32nd in 2005. ... New York (Vocus) April 19, 2010 -- ... 18th out of 146 medical schools and schools of osteopathic medicine nationwide, jumping from 32nd in ...
... ... leadership through technology innovation and improved usability. , ... (PRWEB) April 19, 2010 -- FileTrail, ... announced the release of FileTrail 4.0. This new release extends the company,s leadership ...
... ... the Easy Water system in Austin, Texas. The Easy Water system is a revolutionary alternative ... as calcium and magnesium in your water, without them resulting in hard water buildup. ... Austin, Texas -- 1st Plumbing ...
Cached Medicine News:Health News:Fatal Choking a Real Risk Among Toddlers 2Health News:Fatal Choking a Real Risk Among Toddlers 3Health News:Free UAB service to help parents advocate for safer playgrounds, gyms 2Health News:Mount Sinai School of Medicine Ranked in the Top 20 Best Medical Schools by US News & World Report 2Health News:Newest Release of FileTrail Sets New Standard in Global Physical Records Management and File Tracking 2Health News:Newest Release of FileTrail Sets New Standard in Global Physical Records Management and File Tracking 3Health News:1st Plumbing Services Selected to be Exclusive Dealer in Austin, Texas for Installation of Easy Water No-Salt Water Conditioning System 2Health News:1st Plumbing Services Selected to be Exclusive Dealer in Austin, Texas for Installation of Easy Water No-Salt Water Conditioning System 3
Foreign body spud very thin, lightly curved and rounded tip....
... premium high water content ... permeability. Standard one fit ... the following therapeutic conditions: ... bullous keratopathy, recurrent ulcers, ...
Bandage lenses....
Guthrie skin hook with 2 prongs....
Medicine Products: